UK drug prices down 21% but Britain still spends less on medicines than Europe

23 April 2006

Although the prices of medicines in the UK are more than 21% lower in real terms than they were 10 years ago, the percentage of the Department of Health's budget that the National Health Service spends on medicines has dropped to 11%, according to new figures from the the Association of the British Pharmaceutical Industry.

These figures also confirm that the UK spends less on medicines than most other European countries, with the annual cost of prescriptions written by British doctors averaging just L205 ($357.40) per person. This is despite the fact that the number of NHS prescriptions dispensed increased by 37 million last year to 826 million in total.

The balance of trade in pharmaceuticals - last year the highest of any sector in UK industry - has shown a decline. Medicines earned a trade surplus for the UK of L3.42 billion in 2005, a drop of 8% on the previous year, when the figure stood at L3.71 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight